4.7 Article

Assessment of 9-OH- and 7,8-diol-benzo[a]pyrene in Blood as Potent Markers of Cognitive Impairment Related to benzo[a]pyrene Exposure: An Animal Model Study

期刊

TOXICS
卷 9, 期 3, 页码 -

出版社

MDPI
DOI: 10.3390/toxics9030050

关键词

benzo[a]pyrene; oral exposure; 9-OHbenzo[a]pyrene 7; 8-diol-benzo[a]pyrene; biomarker of neurotoxicity; cognitive impairments; NMDA receptor; metabolism

资金

  1. Fonds National de Recherche Luxembourg: FNR-CORE [C16/BM/11342695]
  2. Fonds National de Recherche Luxembourg: FNR INTER [INTER/ANR/16/11568350]
  3. Luxembourg Institute of Health
  4. Ministry of Higher Education and Research of Luxembourg
  5. Ministere de l'Enseignement superieur et de la Recherche in France

向作者/读者索取更多资源

Research suggests that B[a]P may accelerate the onset of brain tumors and neurobehavioral disturbances, with direct neurotoxic effects on the central and peripheral nervous systems, and potentially indirect effects through other organs. The brain has the ability to metabolize B[a]P, leading to significant overexpression of genes in certain brain regions at higher doses. Mice showed reduced anxiety and dose-dependent changes in Nmda subunit expression in cognition-related areas at higher doses, with potential metabolites in serum serving as biomarkers for B[a]P-induced cognitive impairments in the future.
The potent neurotoxicity of benzo[a]pyrene (B[a]P) has been suggested to be a susceptibility factor accelerating the onset of brain tumours and the emergence of neurobehavioural disturbances. B[a]P has been shown to be neurotoxic, acting directly on both the central and peripheral nervous systems, as well as indirectly via peripheral organs like liver and gut. By using a realistic B[a]P exposure scenario (0.02-200 mg/kg/day, 10 days) in mice, we elucidated brain-specific B[a]P metabolism and at identified hydroxylated B[a]P metabolites in serum which could be used as markers of cognitive impairment. Repeated oral administration of B[a]P led to, at the doses of 20 and 200 mg/kg/day, significant overexpression of Cyp1a1/Cyp1b1 in 2 out of the 3 brain regions considered, thereby suggesting the ability of the brain to metabolize B[a]P itself. At the same doses, mice exhibited a reduction in anxiety in both the elevated plus maze and the hole board apparatus. Concomitantly, B[a]P triggered dose-dependent changes in Nmda subunit expression (Nr1 and Nr2a/Nr2b) in areas involved in cognition. We detected 9-OH-B[a]P and 7,8-diol-B[a]P in serum at the level for which cognitive impairment was observed. We suggest that these metabolites may, in the future be exploited as potent biomarkers of B[a]P-induced cognitive impairments.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据